We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
5,180.25 +12.75 (+0.25%) Dow Futures
38,318.00 +80.00 (+0.21%) Nasdaq Futures
18,229.75 +50.50 (+0.28%) Russell 2000 Futures
2,031.30 +11.50 (+0.57%) Crude Oil
85.38 -0.28 (-0.33%) Gold
2,371.20 -2.90 (-0.12%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 759.59 |
| Open | 759.57 |
| Bid | 745.00 x 1000 |
| Ask | 751.49 x 1100 |
| Day's Range | 749.78 - 763.50 |
| 52 Week Range | 367.35 - 800.78 |
| Volume | |
| Avg. Volume | 3,072,103 |
| Market Cap | 714.634B |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | 129.82 |
| EPS (TTM) | 5.79 |
| Earnings Date | Apr 30, 2024 |
| Forward Dividend & Yield | 5.20 (0.69%) |
| Ex-Dividend Date | Feb 14, 2024 |
| 1y Target Est | 825.07 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for LLY
Related Research
- Eli Lilly and CompanyTechnical Assessment: Neutral in the Intermediate-TermIt was another week of all-time highs, with the weekly winning streak for the S&P 500 (SPX) continuing. The SPX has moved higher in 17 out of 21 weeks, with a 27% gain during that period. The Nasdaq 100 (QQQ) and the Nasdaq are also 17 out of 21, soaring 30%. The S&P 400 prints the same story, with a 29% pop. Index price volatility is almost undetectable, although there has been some decent volatility, both up and down, among individual stocks. We saw one day of strong breadth on Wednesday and one weak day on Friday.RatingFair ValueEconomic Moat21 days agoArgus Research
Insider MonkeyJim Cramer’s 10 Favorite Healthcare Stock Picks in 2024
In this article, we will take a detailed look at Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024. For a quick overview of such stocks, read our article Jim Cramer’s 5 Favorite Healthcare Stock Picks in 2024. Jim Cramer kicked off 2024 with a positive note for the healthcare sector, saying in a program in January that the […]
Motley Fool3 Magnificent Stocks That Could Double or More by 2030
There's no guarantee these stocks will double by 2030, but their growth prospects look great.
BloombergEli Lilly, Novo Euphoria Risks Disappointing Investors, Goldman Says
(Bloomberg) -- The weight loss drug frenzy that’s driven Eli Lilly & Co. and Novo Nordisk A/S to record peaks is raising the stakes for investors, according to Goldman Sachs Group Inc. analysts.Most Read from BloombergIsrael Versus Iran — What an Open War Between Them Could Look LikeTexas Warns of Possible Power Emergency Next WeekBiden Returns to White House as Israel Braces for Iran ResponseIsrael, Allies Mostly Block Unprecedented Attack From IranA $150 Billion Fortune Bolsters Qatari Royals
TheStreetShark Tank's Mark Cuban speaks out on weight-loss drugs
A conversation TheStreet engaged in with Cuban about weight-loss drugs shifted from Novo Nordisk's Ozempic to something new from Eli Lilly.
ZacksHere is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
BioPharma DiveEuropean regulator concludes no suicide link to obesity drugs
The decision clears a concern hanging over GLP-1 medicines like Ozempic since reports of suicidal ideation and self-harm among people taking the drugs surfaced in July.
Investor's Business DailyIs Eli Lilly Stock A Buy Or A Sell After FDA Delays Its Alzheimer's Drug Decision?
The FDA will now hold an advisory committee meeting to discuss Eli Lilly's Alzheimer's drug, donanemab. Is Eli Lilly stock a buy or a sell?
ZacksEli Lilly (LLY) Increases Despite Market Slip: Here's What You Need to Know
Eli Lilly (LLY) reachead $761.98 at the closing of the latest trading day, reflecting a +0.63% change compared to its last close.
Insider MonkeyInsiders are Piling into These 10 Healthcare Stocks in 2024
In this article, we will take a detailed look at Insiders are Piling into These 10 Healthcare Stocks in 2024. For a quick overview of such stocks, read our article Insiders are Piling into These 5 Healthcare Stocks in 2024. Healthcare investors were nervous when 2024 started, since election years usually don’t bode well for healthcare stocks. But […]
MarketWatchThis weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
GLP-1 medications will likely expand beyond their current uses for diabetes or weight loss, according to money managers at Tema
Morningstar Rating
Rating
Fair Value
Economic Moat
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| BMY Bristol-Myers Squibb Company | |||
| MRK Merck & Co., Inc. | |||
| ABT Abbott Laboratories | |||
| AMGN Amgen Inc. | |||
| JNJ Johnson & Johnson |
Similar to LLY
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| PFE Pfizer Inc. | |||
| ABBV AbbVie Inc. | |||
| JNJ Johnson & Johnson | |||
| MRK Merck & Co., Inc. | |||
| AMGN Amgen Inc. |
Analyst Price Targets (24)
Upgrades & Downgrades
| Maintains | Goldman Sachs: Neutral to Neutral | 4/11/2024 | |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 | |
| Upgrade | Erste Group: Hold to Buy | 4/3/2024 | |
| Maintains | Citigroup: Buy to Buy | 4/2/2024 | |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2024 | |
| Reiterates | Truist Securities: Buy to Buy | 3/22/2024 |
Company Profile
Lilly Corporate Center
Indianapolis, IN 46285
United States
317 276 2000
https://www.lilly.com
Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full Time Employees: 43,000
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
